ClinicalTrials.gg
RecruitingNCT00307281Updated Oct 6, 2026

Emphysema Research Registry and Biosample Repository

An observational study in Emphysema, Chronic Obstructive Pulmonary Disease and Chronic Bronchitis, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Pittsburgh · Observational

From the registry’s dates

  • Started Aug 2000; still recruiting 26 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
3,000
Ages
21 Years and older
Sex
All
01

Study summary

The Comprehensive Lung Center (CLC) at the University of Pittsburgh Medical Center (UPMC Health System) provides patients with any type of breathing or lung disorder a full range of diagnostic and therapeutic services. The Emphysema/COPD Research Center (ECRC) is a specialty clinic, within this center, that attempts to advance the understanding of emphysema and to evaluate new therapies for patients with emphysema. The Emphysema Research Registry will enable pulmonary research physicians to: 1) gather information and create a research registry of people who have been diagnosed with emphysema; 2) utilize this research registry with the purpose of conducting research that attempts to advance the understanding of emphysema and to evaluate new therapies; and, 3) use the research registry to identify potential candidates for future research programs. These aims will be achieved by the collection of DNA (genetic material)for analysis and storage in addition to pulmonary function tests and other medical information.

Read the detailed description

The Emphysema/COPD Research Center will enroll up to 3000 subjects at the University of Pittsburgh. The experimental procedures that will be conducted as a part of the Emphysema Research Registry include gathering basic personal information (e.g., name, address, phone number, etc.), asking basic screening questions (which may involve the examination of past, current, and future medical records with an authorized release and the collection of personally identifiable medical record information), completing two breathing questionnaires, performing screening lung function tests to determine breathing capacity and blood oxygen levels, to have blood drawn, to complete a measurement of leg muscle strength, and to have a measurement of body fat.

The breathing questionnaires are known as the St. George's Respiratory Questionnaire (SGRQ), the Medical Research Council Dyspnea Questionnaire (MRCDQ) and COPD assessment Test (CAT). These are paper and pencil questionnaires that inquire about respiratory symptoms, quality of life, and shortness of breath.

Breathing tests are routine clinical tests that measure lung function; spirometry (measures the ability to move air in and out of the lungs), lung volumes (measures the amount of air trapped in the lungs), diffusing capacity (measures how well lungs transfer oxygen to blood), forced oscillometry testing (measures respiratory resistance), and pulse oximetry (measures blood oxygen levels). In addition, subjects will be asked to inhale two puffs of albuterol, which is an inhaled medicine (bronchodilator) that may open up breathing passages, and to repeat some of the breathing tests.

The initial blood work will consist of two samples. The first sample will examine routine tests such as blood chemistries (such as sodium and potassium), hemoglobin, blood count, and blood sugar. The second sample will involve DNA testing. The DNA in your cells is what determines your genetic makeup. The DNA studies that will be done for this Research Registry will be restricted to studies of genetics associated with COPD. The total amount of blood drawn will be 5 tablespoons or less. A separate consent form, Consent 2, addresses this second blood draw in detail. In addition to the initial blood draw, the participant will be asked to contact the center when they are experiencing a COPD exacerbation (increased cough, change in sputum, shortness of breath, etc.). At that time, the participant will be asked to either come to the clinic or allow a study coordinator to go to them and obtain an additional sample of blood. The total amount of this sample will be less than 2 tablespoons. Biologic samples (serum plasma) will be under the control of the principal investigator of this research project. To protect confidentiality, all personal identifiers (i.e. name, social security number, birth date) will be removed (de-identified) and replaced with a specific code number. The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location. The investigators on this study will keep the samples indefinitely. Biological samples may (or will or will not) be given to investigators outside of UPMC or may be utilized in future studies.

Leg muscle strength will be measured using an isokinetic dynamometer (MERAC, Universal, Cedar Rapids, IA) in all subjects. Strength will be measured as peak angular force (Newton-m) generated at an angular velocity of 60º/sec during three maximal continuous repetitions. Subjects will be provided standardized instructions and perform practice maneuvers to ensure smooth torque curves.

Body fat testing, also known as Fat Free Mass (FFM) testing, will be measured using a single frequency bioelectrical impedance method in the supine position, as the mean of two measurements (one on each side of the body), using equipment previously used by the Emphysema Research Center (BIA 101/s RJL-Systems, Detroit, MI). The FFM index will be calculated by dividing FFM by height in meters2 as an accurate measure of muscle mass.

All study procedures including Informed Consent, breathing questionnaires, breathing tests, blood work, leg muscle strength testing, and body fat testing will be conducted at the Emphysema/COPD Research Center, located in Suite 1211, Kaufmann Building. The informed consent usually takes 30 minutes, the Patient Data Form will require 5 minutes to fill out, the two breathing questionnaires will take 15 minutes, the screening lung function tests usually take less than 1 hour, the blood work will take 15 minutes, the leg muscle strength testing will take 10 minutes, and the body fat testing will take 5 minutes.

The information from each subject will be entered into the Emphysema Research Registry. The information will be held here until a research protocol is developed or an outside investigator approaches Dr. Frank C. Sciurba. The information gathered (basic personal information, basic screening questions, breathing questionnaires, screening lung function tests, blood work, leg muscle strength, and body fat) will be updated periodically, based on investigator need.

02

Conditions studied

  • Emphysema
  • Chronic Obstructive Pulmonary Disease
  • Chronic Bronchitis
03

In context

Emphysema

382 studies on the registry are indexed under Emphysema; 59 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 131 across 111 observational studies indexed under Emphysema.

Browse Emphysema studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Current and former smokers with a 10 pack year tobacco history.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients would be required to have based on at least one of the following: clinical history, pulmonary function results, or radiographic results.

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
3,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Registry

    10 pack year tobacco smoking history required, current or former smokers accepted.

06

What researchers measure

Primary outcomes

  1. To gather information and create a research registry of people who have been diagnosed with emphysema and a control cohort of research participants without lung diseases,

    This research registry will allow us to to advance the understanding of emphysema and to evaluate new therapies for patients with emphysema.

    Time frame: Indefinite

Secondary outcomes

  1. To continue communications with past, present, and future research participants.

    To utilize this research registry with the purpose to learn more about the pathogenesis of emphysema and the efficacy of new therapies, and to provide a mechanism for improving the quality of treatment for emphysema and advance the field.

    Time frame: Indefinite

07

Study locations

1 of 1 sites recruiting
  • University of Pittsburgh Emphysema/COPD Research Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • · Contactecrc@upmc.edu · 412-692-4800
    • · Contactecrc@upmc.edu · 1-866-948-COPD(2673)
    • Frank C. Sciurba, MD · Principal investigator
    • Jessica M. Bon, MD · Sub investigator
    • Divay Chandra, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00307281
Responsible party
Frank C Sciurba (Director, Emphysema/COPD Research Center, University of Pittsburgh) — Principal investigator
First posted
Mar 27, 2006
Start date
Aug 2000
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Paula Consolaro, CCRC
Contact
consolaropj@upmc.edu
412-692-4800
Vera Iouchmanov, BS
Contact
iouchmanovvl@upmc.edu
412-864-3052
Frank C. Sciurba, MD
principal investigator · University of Pittsburgh Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion